Best eQMS for FDA 21 CFR Part 11 Compliance

21 CFR Part 11 covers three subparts. §11.10 (Controls for Closed Systems): validation, records protection, audit trails, system access controls, training, written policies. §11.50 (Signature Manifestations): signed records must show printed name, date and time, and meaning of signature. §11.70 (Signature / Record Linking): signatures are linked to records they apply to. §11.100–11.300 (Electronic Signatures): unique to one individual, password / re-authentication, periodic re-validation. The eQMS must implement all of these in the platform plus document them in validation evidence.

All major life-sciences eQMS vendors publicly claim Part 11 alignment. Compliance is ultimately the customer’s responsibility — Part 11 is implemented through a combination of platform capability (closed-system controls, audit trails, e-signatures), customer SOPs (administrative controls, training, periodic review), and validation evidence (system requirements, test scripts, audit-trail testing). During procurement, ask each vendor for a Part 11 checklist and an Audit Trail Specification (ATS) for the modules in scope. Complere ships both as part of the validation pack on day one.

Part 11 alignment means the platform was built to implement Part 11 controls — audit trail, e-signatures, access controls, validation. Part 11 compliance is achieved when the platform plus the customer’s SOPs, training, validation evidence, and operational controls together meet the regulation. No vendor can ship “Part 11 compliance” as a feature; vendors ship platform capability that customers operationalise inside their quality system.

Yes. Complere ships a Part 11 checklist (mapping each subpart and clause to platform implementation evidence) and an Audit Trail Specification (ATS) per module as part of the standard validation pack. The pack includes VMP, URS, RA, TM, IQ, OQ, PQ, Part 11 checklist, and ATS. This means the customer has documented evidence on day one for §11.10 controls, §11.50 manifestation, §11.70 linking, and §11.100–11.300 signatures.

FDA Computer Software Assurance (CSA) Final Guidance (issued 2022) is a risk-based approach to validation that complements Part 11. CSA reduces the testing burden on low-risk system functions while keeping rigorous validation on high-risk functions. Part 11 controls (audit trail, e-signatures, access) remain mandatory. Complere uses a CSA-aligned risk-based approach to scope validation depth per requirement, with full CSV protocol pack delivered for every module.

Part 11 (US FDA) and Annex 11 (EU GMP) both govern computerised systems in regulated life sciences, but they originate from different regulatory bodies and emphasise slightly different controls. Part 11 focuses on electronic records and signatures (audit trail, e-signature manifestation, signer authentication). Annex 11 covers the broader system lifecycle (validation, risk management, supplier responsibilities, data integrity, business continuity, IT infrastructure). Most platforms claiming Part 11 alignment also align to Annex 11 because the underlying technical controls overlap substantially. Complere is aligned to both.

Both, depending on use. §11.10 covers controls for closed-system electronic records (audit trails, access controls, validation). §11.50, §11.70, §11.100, and §11.200 cover electronic signatures specifically — when an organisation chooses to use them in place of handwritten signatures. If your processes still use wet signatures on printed records you may not need §11.50 / §11.100 enforcement, but if you sign anything electronically (approval workflows, training records, controlled document releases) the e-signature subparts apply.

An Audit Trail Specification (ATS) documents what the eQMS audit trail captures (record creates, updates, deletes, views, e-signature events), retention period, immutability mechanism, export format, and reviewer workflow. Auditors and inspectors ask for the ATS to verify §11.10(e) compliance — that the audit trail is computer-generated, time-stamped, and includes operator identification. Complere ships an ATS per module as part of the validation pack on day one. Most competitors document audit-trail behaviour ad-hoc or as part of broader documentation; few ship a formal ATS.

Part 11 itself does not set a record-retention period. Retention is governed by the underlying GxP regulation — e.g. 21 CFR Part 211 (current Good Manufacturing Practice for pharmaceuticals) requires batch records retained for 1 year past expiry; 21 CFR Part 820 / FDA QMSR requires DHF records retained for the lifetime of the device plus 2 years; ISO 13485 requires records retained for at least the lifetime of the device but not less than 2 years from product release. The eQMS must retain records (and audit trail) for whatever period the underlying regulation requires, with full data integrity (ALCOA+) preserved across retention.

FDA inspectors evaluating Part 11 compliance typically ask for: (1) the validation pack proving the system was validated for intended use (URS, RA, IQ, OQ, PQ); (2) the audit trail for specific records, including who made each change and when; (3) e-signature manifestation showing printed name, date, and meaning; (4) access control records demonstrating system access is restricted to authorised users; (5) training records for everyone using the system; and (6) the SOP governing system administration. Most findings are not platform deficiencies but procedural gaps — missing training, undocumented user provisioning, audit-trail review backlog. The eQMS makes the technical evidence available; quality SOPs make it operational.